← Back to Search

Other

NMRA-335140 for Depression

Verified Trial
Phase 3
Recruiting
Research Sponsored by Neumora Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 54
Awards & highlights

Study Summary

This trial extends a study to evaluate the safety, tolerability and effectiveness of a treatment for major depressive disorder (MDD). Eligible participants who completed a parent study will be enrolled.

Who is the study for?
This trial is for people who have major depressive disorder and completed a previous NMRA-335140 study. They must have signed an informed consent form, agree to follow medication restrictions, and comply with contraception requirements from the earlier study.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of a drug called NMRA-335140 over 52 weeks in participants with major depressive disorder who previously took part in related studies.See study design
What are the potential side effects?
Since this summary does not provide specific side effects of NMRA-335140, it's important for interested individuals to ask about potential risks before joining.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 54
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 54 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales
Secondary outcome measures
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time.
Change from Baseline in PHQ-9 Anhedonia Item #1 over time.
Change from Baseline in the Clinical Global Impression Scale of Severity (CGI-S)
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NMRA-335140 80 milligrams (mg) once daily (QD)Experimental Treatment1 Intervention
Participants will receive a NMRA-335140 tablet at a dose of 80 mg once daily (QD) during a 52-week treatment period.

Find a Location

Who is running the clinical trial?

Neumora Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
1,200 Total Patients Enrolled
4 Trials studying Depression
1,200 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently accepting volunteers for this experiment?

"Per the information on clinicaltrials.gov, this medical trial is currently recruiting volunteers. The initial post was published on November 10th 2023 and the most recent update came out on November 21st 2023."

Answered by AI

Are there any potential dangers associated with taking NMRA-335140 80 mg QD?

"NMRA-335140 80 milligrams (mg) administered once daily (QD) has previously demonstrated to be safe in clinical trials, thus earning a score of 3."

Answered by AI

Is the age eligibility threshold for this experiment greater than 25 years?

"The accepted age range for this research is 18 to 65. Those below the former or above the latter can look into 229 and 1054 trials respectively that may be suitable for them."

Answered by AI

How many participants are currently included in this research endeavor?

"Affirmative. According to the information on clinicaltrials.gov, this research endeavour is actively looking for enrollees; it was initially posted on November 10th 2023 and most recently updated on November 21st 2023. 650 participants are needed from 1 location."

Answered by AI

Is there an opportunity to participate in this experiment?

"For this clinical trial, 650 individuals aged 18-65 with a current diagnosis of depression must be recruited. Furthermore, they need to have participated in one of the Phase 3 MDD studies (NMRA-335140-301, NMRA-335140-302 or NMRA 335140 -303), sign an ICF and abide by contraception protocol described earlier as well as any concomitant medication/therapy restrictions mentioned."

Answered by AI

Who else is applying?

What site did they apply to?
Neumora Investigator Site
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

Why did patients apply to this trial?

Multiple anlti-depressents have been taken over the last 30 years; most have steadily lessened their effectiveness over time.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Study to Assess the Safety and Effectiveness of NMRA-335140-501
2023. "Study to Assess the Safety and Effectiveness of NMRA-335140-501". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06029439.
All > Depression Los Angeles > New Orleans
~433 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top